We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
GTBP | GT Biopharma Inc | 7.23 | 4.11 | 131.73% | 12,414,534 |
MMV | MultiMetaVerse Holdings Ltd | 1.15 | 0.5592 | 94.65% | 13,933,115 |
FFIE | Faraday Future Intelligent Electric Inc | 1.9997 | 0.9697 | 94.15% | 103,268,223 |
CRKN | Crown Electrokinetics Corporation | 0.2634 | 0.0924 | 54.04% | 164,662,837 |
TANH | Tantech Holdings Ltd | 0.955 | 0.298 | 45.36% | 7,039,367 |
MTC | MMTec Inc | 9.5034 | 2.49 | 35.57% | 758,519 |
NKGN | NKGen Biotech Inc | 1.45 | 0.33 | 29.46% | 5,181,951 |
CNEY | CN Energy Group Inc | 0.852 | 0.187 | 28.12% | 3,743,987 |
HUBCW | Hub Cyber Security Ltd | 0.03 | 0.0062 | 26.05% | 100 |
SINT | SiNtx Technologies Inc | 0.1069 | 0.0219 | 25.76% | 24,592,135 |
HLTH | Cue Health Inc | 0.12 | 0.0236 | 24.48% | 45,574,051 |
Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future,” “FF,” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that it is scheduled to have a conference call on its fourth quarter and full year 2023 results after market close on Tuesday, May 28, 2024 at 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time).
SHANGHAI, May 20, 2024 /PRNewswire/ -- MultiMetaVerse Holdings Limited ("MMV" or the "Company"), a leading animation and entertainment company for young consumers in China, announced today that it has entered into a non-binding term sheet (the "Term Sheet") for the acquisition (the "Proposed Transaction") of 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries (collectively "Bowong AI") by the issuance of the Company's Class A ordinary shares to the shareholders of Bowong AI as consideration (the "Consideration Shares"), the amount of which will be determined based on further due diligence and negotiation. The Consideration Shares shall be subject to ...
- European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 revenue guidance paused - WARREN, N.J., May 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation. As a result, Translarna remains on the market and available for patients in Europe consistent with its current marketing authorization. The EC ...
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2MIRA continues to advance studies of Ketamir-2 in animal studies while improving manufacturing optimization as the company prepares for human testing in 2025.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
LWLG | Lightwave Logic Inc | 99 | |
COOP | Mr Cooper Group Inc | 58 | |
NSAV | NSAV Holding Inc | 85 | |
4 | RNVA | Rennova Health Inc | 41 |
5 | SPZI | SPOOZ Inc | 24 |
6 | ILST | International Star Inc | 4 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 67,036.13 | 875.83 | 1.32% | 1.32T | 2,639,547,806 |
ETH | Ethereum | 3,088.71 | 8.71 | 0.28% | 371.2B | 1,410,430,019 |
USDT | Tether USD | 0.99999 | -0.00001 | 0.00% | 97.84B | 183,811,607 |
BNB | Binance Coin | 571.52 | -2.02 | -0.35% | 90.21B | 147,555,402 |
SOL | Solana | 176.98 | 1.88 | 1.07% | 78.09B | 1,174,249,281 |
STETH | stETH | 3,088.30 | 43.41 | 1.43% | 30.25B | 7,489,846 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 583,095,126 |
XRP | Ripple | 0.5121 | -0.00201 | -0.39% | 27.92B | 202,635,625 |
TONCOIN | Wrapped TON Coin | 6.39 | 0.022512 | 0.35% | 22.45B | 68,333,030 |
DOGE | Dogecoin | 0.15132 | 0.00232 | 1.56% | 21.66B | 218,424,485 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions